Journal Watch

Thrombotic microangiopathies

Complement Activation and Thrombotic Microangiopathies.
Author(s): Palomo M, Blasco M, Molina P, Lozano M, Praga M, Torramade-Moix S, Martinez-Sanchez J, Cid J, Escolar G, Carreras E, Paules C, Crispi F, Quintana LF, Poch E, Rodas L, Goma E, Morelle J, Espinosa M, Morales E, Avila A, Cabello V, Ariceta G, Chocron S, Manrique J, Barros X, Martin N, Huerta A, Fraga-Rodriguez GM, Cao M, Martin M, Romera AM, Moreso F, Manonelles A, Gratacos E, Pereira A, Campistol JM, Diaz-Ricart M
Source: Clin J Am Soc Nephrol 2019 Nov 6;
Publication date: 2019-11-6
Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature.
Author(s): Haskin O, Falush Y, Davidovits M
Source: Pediatr Nephrol 2019 Sep 13;
Publication date: 2019-09-13
New insights into the pathogenesis of Streptococcus pneumoniae-associated hemolytic uremic syndrome.
Author(s): Scobell RR, Kaplan BS, Copelovitch L
Source: Pediatr Nephrol 2019 Sep 13;
Publication date: 2019-09-13
Profiles of Coagulation and Fibrinolysis Activation-Associated Molecular Markers of Atypical Hemolytic Uremic Syndrome in the Acute Phase.
Author(s): Sakurai S, Kato H, Yoshida Y, Sugawara Y, Fujisawa M, Yasumoto A, Matsumoto M, Fujimura Y, Yatomi Y, Nangaku M
Source: J Atheroscler Thromb 2019 Sep 4;
Publication date: 2019-09-4
Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome.
Author(s): Cavero T, Arjona E, Soto K, Caravaca-Fontán F, Rabasco C, Bravo L, de la Cerda F, Martín N, Blasco M, Ávila A, Huerta A, Cabello V, Jarque A, Alcázar C, Fulladosa X, Carbayo J, Anaya S, Cobelo C, Ramos N, Iglesias E, Baltar J, Martínez-Gallardo R, Pérez L, Morales E, González R, Macía M, Draibe J, Pallardó L, Quintana LF, Espinosa M, Barros X, Pereira F, Cao M, Moreno JA, Rodríguez de Córdoba S, Praga M
Source: Kidney Int 2019 May 31;
Publication date: 2019-05-31
Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy.
Author(s): Zheng L, Zhang D, Cao W, Song W, Zheng XL
Source: Blood 2019 Aug 13;
Publication date: 2019-08-13
Thrombotic microangiopathy associated with anti-neutrophil cytoplasmic antibody-associated vasculitis: a French nationwide retrospective case-control study and literature review.
Author(s): Dellal A, Bige N, Hilliquin P, Boffa JJ, Rondeau E, Hatron PY, Deligny C, Bally S, Maury E, Veyradier A, Buob D, Fain O, Coppo P, Mekinian A
Source: Rheumatology (Oxford) 2019 Apr 28;
Publication date: 2019-04-28
Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura.
Author(s): Chander DP, Loch MM, Cataland SR, George JN
Source: N Engl J Med 2019 Jul 4;381(1):92-94
Publication date: 2019-07-4
C3 levels and acute outcomes in Shiga toxin-related hemolytic uremic syndrome.
Author(s): Balestracci A, Meni Bataglia L, Toledo I, Beaudoin L, Alvarado C
Source: Pediatr Nephrol 2019 Sep 2;
Publication date: 2019-09-2
Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study.
Author(s): Monet-Didailler C, Chevallier A, Godron-Dubrasquet A, Allard L, Delmas Y, Contin-Bordes C, Brissaud O, Llanas B, Harambat J
Source: Nephrol Dial Transplant 2019 Aug 14;
Publication date: 2019-08-14
Post-Surgical Thrombotic Microangiopathy: Case Series and Review of the Literature.
Author(s): Sridharan M, Hook CC, Leung N, Winters JL, Go RS
Source: Eur J Haematol 2019 Jun 28;
Publication date: 2019-06-28
Monoclonal gammopathy-associated thrombotic microangiopathy.
Author(s): Yui JC, Garceau D, Jhaveri KD, Wanchoo R, Bijol V, Glezerman I, Hassoun H, Dispenzieri A, Russell SJ, Leung N
Source: Am J Hematol 2019 Jun 30;
Publication date: 2019-06-30
Escherichia coli-associated hemolytic uremic syndrome and severe chronic hepatocellular cholestasis: complication or side effect of eculizumab?
Author(s): Mauras M, Bacchetta J, Duncan A, Lavocat MP, Rohmer B, Javouhey E, Collardeau-Frachon S, Sellier-Leclerc AL
Source: Pediatr Nephrol 2019 Jul;34(7):1289-1293
Publication date: 2019-07
Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
Author(s): Menne J, Delmas Y, Fakhouri F, Licht C, Lommelé Å, Minetti EE, Provôt F, Rondeau E, Sheerin NS, Wang J, Weekers LE, Greenbaum LA
Source: BMC Nephrol 2019 Apr 10;20(1):125
Publication date: 2019-04-10
Hemolytic uremic syndrome in a developing country: Consensus guidelines.
Author(s): Bagga A, Khandelwal P, Mishra K, Thergaonkar R, Vasudevan A, Sharma J, Patnaik SK, Sinha A, Sethi S, Hari P, Dragon-Durey MA
Source: Pediatr Nephrol 2019 Aug;34(8):1465-1482
Publication date: 2019-08
Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis.
Author(s): Gonzalez Suarez ML, Thongprayoon C, Mao MA, Leeaphorn N, Bathini T, Cheungpasitporn W
Source: J Clin Med 2019 Jun 27;8(7)
Publication date: 2019-06-27
Clinical and Immunological Profile of Anti-factor H Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database.
Author(s): Puraswani M, Khandelwal P, Saini H, Saini S, Gurjar BS, Sinha A, Shende RP, Maiti TK, Singh AK, Kanga U, Ali U, Agarwal I, Anand K, Prasad N, Rajendran P, Sinha R, Vasudevan A, Saxena A, Agarwal S, Hari P, Sahu A, Rath S, Bagga A
Source: Front Immunol 2019;10:1282
Publication date: 2019
An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy.
Author(s): Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G
Source: Clin Kidney J 2019 Jun;12(3):333-337
Publication date: 2019-06
Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safety.
Author(s): Khandelwal P, Thomas CC, Rathi BS, Hari P, Tiwari AN, Sinha A, Bagga A
Source: J Clin Apher 2019 Jun 7;
Publication date: 2019-06-7
Deleterious Impact of a Novel CFH Splice Site Variant in Atypical Hemolytic Uremic Syndrome.
Author(s): Schönauer R, Seidel A, Grohmann M, Lindner TH, Bergmann C, Halbritter J
Source: Front Genet 2019;10:465
Publication date: 2019
Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview.
Author(s): Kakoullis L, Papachristodoulou E, Chra P, Panos G
Source: J Infect 2019 May 28;
Publication date: 2019-05-28
Rab7b participation on the TLR4 (Toll-like receptor) endocytic pathway in Shiga toxin-associated Hemolytic Uremic Syndrome (HUS).
Author(s): Lafalla Manzano AF, Gil Lorenzo AF, Bocanegra V, Costantino VV, Cacciamani V, Benardon ME, Vallés PG
Source: Cytokine 2019 Sep;121:154732
Publication date: 2019-09
Predicting Hemolytic Uremic Syndrome and Renal Failure in Shiga Toxin-Producing Escherichia coli Infected Children.
Author(s): McKee RS, Schnadower D, Tarr PI, Xie J, Finkelstein Y, Desai N, Lane RD, Bergmann KR, Kaplan RL, Hariharan S, Cruz AT, Cohen DM, Dixon A, Ramgopal S, Rominger A, Powell EC, Kilgar J, Michelson KA, Beer D, Bitzan M, Pruitt CM, Yen K, Meckler GD, Plint AC, Bradin S, Abramo TJ, Gouin S, Kam AJ, Schuh A, Balamuth F, Hunley TE, Kanegaye JT, Jones NE, Avva U, Porter R, Fein DM, Louie JP, Freedman SB
Source: Clin Infect Dis 2019 May 24;
Publication date: 2019-05-24
Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
Author(s): Kaczmarek V, Holle J, Astudillo R, Kempf C, Bufler P, Müller D
Source: Pediatr Nephrol 2019 Jun 8;
Publication date: 2019-06-8
The C3a/C3aR axis mediates anti-inflammatory activity and protects against uropathogenic E coli-induced kidney injury in mice.
Author(s): Wu KY, Zhang T, Zhao GX, Ma N, Zhao SJ, Wang N, Wang JX, Li ZF, Zhou W, Li K
Source: Kidney Int 2019 Mar 21;
Publication date: 2019-03-21
Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.
Author(s): Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams CM, Mac Sweeney A, Liao SM, Crowley M, Littlewood-Evans A, Sarret S, Wieczorek G, Perrot L, Dubost V, Flandre T, Zhang Y, Smith RJH, Risitano AM, Karki RG, Zhang C, Valeur E, Sirockin F, Gerhartz B, Erbel P, Hughes N, Smith TM, Cumin F, Argikar UA, Haraldsson B, Mogi M, Sedrani R, Wiesmann C, Jaffee B, Maibaum J, Flohr S, Harrison R, Eder J
Source: Proc Natl Acad Sci U S A 2019 Mar 29;
Publication date: 2019-03-29
Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors.
Author(s): Le Clech A, Simon-Tillaux N, Provôt F, Delmas Y, Vieira-Martins P, Limou S, Halimi JM, Le Quintrec M, Lebourg L, Grangé S, Karras A, Ribes D, Jourde-Chiche N, Rondeau E, Frémeaux-Bacchi V, Fakhouri F
Source: Kidney Int 2019 Mar 15;
Publication date: 2019-03-15
Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.
Author(s): Ueda Y, Miwa T, Ito D, Kim H, Sato S, Gullipalli D, Zhou L, Golla M, Song D, Dunaief JL, Palmer MB, Song WC
Source: Kidney Int 2019 Feb 27;
Publication date: 2019-02-27
Atypical haemolytic uraemic syndrome in the eculizumab era: presentation, response to treatment and evaluation of an eculizumab withdrawal strategy.
Author(s): Neave L, Gale DP, Cheesman S, Shah R, Scully M
Source: Br J Haematol 2019 Mar 27;
Publication date: 2019-03-27
Etiology and Outcomes of Thrombotic Microangiopathies.
Author(s): Bayer G, von Tokarski F, Thoreau B, Bauvois A, Barbet C, Cloarec S, Mérieau E, Lachot S, Garot D, Bernard L, Gyan E, Perrotin F, Pouplard C, Maillot F, Gatault P, Sautenet B, Rusch E, Buchler M, Vigneau C, Fakhouri F, Halimi JM
Source: Clin J Am Soc Nephrol 2019 Mar 12;
Publication date: 2019-03-12
An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.
Author(s): Galbusera M, Noris M, Gastoldi S, Bresin E, Mele C, Breno M, Cuccarolo P, Alberti M, Valoti E, Piras R, Donadelli R, Vivarelli M, Murer L, Pecoraro C, Ferrari E, Perna A, Benigni A, Portalupi V, Remuzzi G
Source: Am J Kidney Dis 2019 Mar 6;
Publication date: 2019-03-6
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.
Author(s): Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, van den Heuvel LP, Wetzels JFM, van de Kar NCAJ, Brüggemann RJ
Source: Clin Pharmacokinet 2019 Feb 13;
Publication date: 2019-02-13
Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice.
Author(s): Smith-Jackson K, Yang Y, Denton H, Pappworth IY, Cooke K, Barlow PN, Atkinson JP, Liszewski MK, Pickering MC, Kavanagh D, Cook HT, Marchbank KJ
Source: J Clin Invest 2019 Mar 1;129(3):1061-1075
Publication date: 2019-03-1
Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.
Author(s): Socié G, Caby-Tosi MP, Marantz JL, Cole A, Bedrosian CL, Gasteyger C, Mujeebuddin A, Hillmen P, Vande Walle J, Haller H
Source: Br J Haematol 2019 Feb 15;
Publication date: 2019-02-15
Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection -is plasma exchange or eculizumab use necessary?
Author(s): Saida K, Ogura M, Kano Y, Ishimori S, Yoshikawa T, Nagata H, Sato M, Kamei K, Ishikura K
Source: BMC Nephrol 2018 Dec 17;19(1):365
Publication date: 2018-12-17
Hemolytic uremic syndrome associated with Bordetella pertussis infection in a 2-month-old infant carrying a pathogenic variant in complement factor H.
Author(s): Madden I, Roumenina LT, Langlois-Meurinne H, Guichoux J, Llanas B, Frémeaux-Bacchi V, Harambat J, Godron-Dubrasquet A
Source: Pediatr Nephrol 2018 Dec 17;
Publication date: 2018-12-17
Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome.
Author(s): Buelli S, Zoja C, Remuzzi G, Morigi M
Source: Microorganisms 2019 Jan 10;7(1)
Publication date: 2019-01-10
Complement Gene Variants and Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study.
Author(s): Frémeaux-Bacchi V, Sellier-Leclerc AL, Vieira-Martins P, Limou S, Kwon T, Lahoche A, Novo R, Llanas B, Nobili F, Roussey G, Cailliez M, Ulinski T, Deschênes G, Alberti C, Weill FX, Mariani P, Loirat C
Source: Clin J Am Soc Nephrol 2019 Jan 23;
Publication date: 2019-01-23
Haptoglobin degradation product as a novel serum biomarker for hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Author(s): Schuh MP, Bennett MR, Lane A, Jodele S, Laskin BL, Devarajan P
Source: Pediatr Nephrol 2018 Dec 19;
Publication date: 2018-12-19
Survey of thrombotic microangiopathy within 1 week after kidney transplantation between 2010 and 2015 in Japan.
Author(s): Satoh S, Saito K, Harada H, Okumi M, Saito M
Source: Clin Exp Nephrol 2018 Dec 11;
Publication date: 2018-12-11
Interleukin-33/ST2 signaling contributes to the severity of hemolytic uremic syndrome induced by enterohemorrhagic Escherichia coli.
Author(s): Yamada S, Shimizu M, Kuroda M, Inoue N, Sugimoto N, Yachie A
Source: Clin Exp Nephrol 2018 Nov 22;
Publication date: 2018-11-22
Long-term outcome of diarrhea-associated hemolytic uremic syndrome is poorly related to markers of kidney injury at 1-year follow-up in a population-based cohort.
Author(s): Monet-Didailler C, Godron-Dubrasquet A, Madden I, Delmas Y, Llanas B, Harambat J
Source: Pediatr Nephrol 2018 Oct 27;
Publication date: 2018-10-27
Emerging Shiga-toxin-producing Escherichia coli serogroup O80 associated hemolytic and uremic syndrome in France, 2013-2016: Differences with other serogroups.
Author(s): Ingelbeen B, Bruyand M, Mariani-Kurkjian P, Le Hello S, Danis K, Sommen C, Bonacorsi S, de Valk H
Source: PLoS One 2018;13(11):e0207492
Publication date: 2018
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.
Author(s): Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ
Source: Pediatr Nephrol 2018 Nov 6;
Publication date: 2018-11-6
Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: A report on its efficacy and safety in two pediatric patients.
Author(s): Genere L, Bacchetta J, Bertrand Y, Javouhey E, Cheikh N, Sellier-Leclerc AL
Source: Arch Pediatr 2018 Nov;25(8):485-488
Publication date: 2018-11
Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome.
Author(s): Sridharan M, Go RS, Abraham RS, Fervenza FC, Sethi S, Bryant SC, Spears GM, Murray DL, Willrich MAV
Source: Mayo Clin Proc 2018 Oct;93(10):1351-1362
Publication date: 2018-10
Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT.
Author(s): Moiseev IS, Tsvetkova T, Aljurf M, Alnounou RM, Bogardt J, Chalandon Y, Drokov MY, Dvirnyk V, Faraci M, Friis LS, Giglio F, Greinix HT, Kornblit BT, Koelper C, Koenecke C, Lewandowski K, Niederwieser D, Passweg JR, Peczynski C, Penack O, Peric Z, Piekarska A, Ronchi PE, Rovo A, Rzepecki P, Scuderi F, Sigrist D, Siitonen SM, Stoelzel F, Sulek K, Tsakiris DA, Wilkowojska U, Duarte RF, Ruutu T, Basak GW
Source: Bone Marrow Transplant 2018 Oct 25;
Publication date: 2018-10-25
Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS).
Author(s): Khalid M, Andreoli S
Source: Pediatr Nephrol 2018 Nov 1;
Publication date: 2018-11-1
Impact of a multidisciplinary team for the management of thrombotic microangiopathy.
Author(s): Uriol Rivera MG, Cabello Pelegrin S, Ballester Ruiz C, López Andrade B, Lumbreras J, Obrador Mulet A, Perez Montaña A, Ferreruela Serlavos M, Ayestarán Rota JI, Ferrer Balaguer J, Delgado Sanchez O, Pallares Ferreres L, Mas Bonet A, Picado Valles MJ, de Gopegui Valero RMR
Source: PLoS One 2018;13(11):e0206558
Publication date: 2018
Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?
Author(s): Vaughn JL, Zhao Q, Epperla N, Puto M, Roddy J, Elder P, Blum W, Klisovic R, Jaglowski S, Penza S, William B, Andritsos L, Brammer JE, Hofmeister C, Efebera Y, Benson D, Devine S, Cataland S, Vasu S
Source: Bone Marrow Transplant 2018 Nov 9;
Publication date: 2018-11-9
Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome.
Author(s): Bu F, Zhang Y, Wang K, Borsa NG, Jones MB, Taylor AO, Takanami E, Meyer NC, Frees K, Thomas CP, Nester C, Smith RJH
Source: J Am Soc Nephrol 2018 Oct 30;
Publication date: 2018-10-30
Glyco-iELISA: a highly sensitive and unambiguous serological method to diagnose STEC-HUS caused by serotype O157.
Author(s): Wijnsma KL, Veissi ST, van Bommel SAM, Heuver R, Volokhina EB, Comerci DJ, Ugalde JE, van de Kar NCAJ, van den Heuvel LPWJ
Source: Pediatr Nephrol 2018 Oct 26;
Publication date: 2018-10-26
A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement.
Author(s): Giordano P, Netti GS, Santangelo L, Castellano G, Carbone V, Torres DD, Martino M, Sesta M, Di Cuonzo F, Resta MC, Gaeta A, Milella L, Chironna M, Germinario C, Scavia G, Gesualdo L, Giordano M
Source: Pediatr Nephrol 2018 Oct 25;
Publication date: 2018-10-25
When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.
Author(s): Olson SR, Lu E, Sulpizio E, Shatzel JJ, Rueda JF, DeLoughery TG
Source: Am J Nephrol 2018;48(2):96-107
Publication date: 2018
Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study.
Author(s): Karnisova L, Hradsky O, Blahova K, Fencl F, Dolezel Z, Zaoral T, Zieg J
Source: Eur J Pediatr 2018 Sep 24;
Publication date: 2018-09-24
Direct-from-stool testing for shiga-toxins by an immunochromatographic assay is insensitive for detection of shigatoxigenic E. coli.
Author(s): Couturier BA, Riley T, Gowans J, Couturier MR
Source: J Clin Microbiol 2018 Oct 3;
Publication date: 2018-10-3
Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury.
Author(s): Cao M, Leite BN, Ferreiro T, Calvo M, Fernández C, Alonso Á, Rodriguez A, Salvador P, Seijo R, Pita S, Arjona E, Rodríguez de Córdoba S, Valdés Cañedo F
Source: Am J Nephrol 2018;48(3):225-233
Publication date: 2018
Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease.
Author(s): Abbas F, El Kossi M, Kim JJ, Sharma A, Halawa A
Source: World J Transplant 2018 Sep 10;8(5):122-141
Publication date: 2018-09-10
Immunological features and functional analysis of anti-CFH autoantibodies in patients with atypical hemolytic uremic syndrome.
Author(s): Guo WY, Song D, Liu XR, Chen Z, Xiao HJ, Ding J, Sun SZ, Liu HY, Wang SX, Yu F, Zhao MH
Source: Pediatr Nephrol 2018 Oct 12;
Publication date: 2018-10-12
A simple prognostic index for Shigatoxin-related hemolytic uremic syndrome at onset: data from the ItalKid-HUS network.
Author(s): Ardissino G, Tel F, Testa S, Paglialonga F, Longhi S, Martelli L, Consolo S, Picicco D, Dodaro A, Daprai L, Colombo R, Arghittu M, Perrone M, Chidini G, Scalia Catenacci S, Cropanese I, Consonni D
Source: Eur J Pediatr 2018 Aug 10;
Publication date: 2018-08-10
Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab.
Author(s): Ağbaş A, Göknar N, Akıncı N, Yıldırım ZY, Taşdemir M, Benzer M, Gökçe İ, Candan C, Küçük N, Uzuner S, Özçelik G, Demirkol D, Sever L, Çalışkan S
Source: Pediatr Nephrol 2018 Aug 29;
Publication date: 2018-08-29
Extra-Renal manifestations of atypical hemolytic uremic syndrome in children.
Author(s): Fidan K, Göknar N, Gülhan B, Melek E, Yıldırım ZY, Baskın E, Hayran M, Gülleroglu K, Özçakar ZB, Ozaltin F, Soylemezoglu O
Source: Pediatr Nephrol 2018 Aug;33(8):1395-1403
Publication date: 2018-08
Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome.
Author(s): Walsh PR, Johnson S
Source: Pediatr Nephrol 2018 Jul 30;
Publication date: 2018-07-30
Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab.
Author(s): Gäckler A, Kaulfuß M, Rohn H, Vogel U, Claus H, Feldkamp T, Kribben A, Witzke O
Source: Nephrol Dial Transplant 2018 Jul 9;
Publication date: 2018-07-9
TREX1 Mutation Causing Autosomal Dominant Thrombotic Microangiopathy and CKD-A Novel Presentation.
Author(s): Gulati A, Bale AE, Dykas DJ, Bia MJ, Danovitch GM, Moeckel GW, Somlo S, Dahl NK
Source: Am J Kidney Dis 2018 Jun 22;
Publication date: 2018-06-22
Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome.
Author(s): Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, Lommelé Å, Kupelian V, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Licht C, Vande Walle J, Frémeaux-Bacchi V
Source: Kidney Int 2018 Jun 12;
Publication date: 2018-06-12
Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia.
Author(s): Ueda Y, Miwa T, Gullipalli D, Sato S, Ito D, Kim H, Palmer M, Song WC
Source: J Am Soc Nephrol 2018 Jun 1;
Publication date: 2018-06-1
Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade.
Author(s): Bitzan M, Hammad RM, Bonnefoy A, Al Dhaheri WS, Vézina C, Rivard GÉ
Source: Pediatr Nephrol 2018 May 4;
Publication date: 2018-05-4
Hemolytic uremic syndrome with dual caution in an infant: cobalamin C defect and complement dysregulation successfully treated with eculizumab.
Author(s): Barlas UK, Kıhtır HS, Goknar N, Ersoy M, Akcay N, Sevketoglu E
Source: Pediatric nephrology (Berlin, Germany)
Publication date: 2018-06
Complete functional characterization of disease-associated genetic variants in the complement factor H gene.
Author(s): Merinero HM, García SP, García-Fernández J, Arjona E, Tortajada A, Rodríguez de Córdoba S
Source: Kidney international
Publication date: 2018-02



European Reference Networks
ERKNet is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Commission.
For more information about the ERNs and the EU health strategy, please visit http://ec.europa.eu/health/ern